More than 580 gene therapy products are under development
in biotech and pharmaceutical companies
for the treatment of more than 240 diseases.
More than 200 of these products are now at the clinical stage.
After releasing our « Landscape in… Gene Therapy Companies » in September, we now offer you an opportunity to get a global overview
of gene therapy products whether they are at the clinical or at the discovery/preclinical stage.
These data support the predominance of AAV-based vectors among the most advanced clinical programs. They also confirm that RNA-based approaches are a dynamic field. Several of the most major drug companies have now chosen to increase and to secure a strategic positioning in this highly-competitive area.
« Gene Therapy Products in Development » will provide you
an accurate breakdown of these programs:
– by type of product
(AAV-based products, lentiviral-based products, antisense products, mRNA, RNAi/siRNA, miRNA, gene editing products….)
– by therapeutic area
(autoimmune diseases, cancers, cardiovascular diseases, hematological diseases,
immunological diseases, lysosomal diseases, CNS diseases, ophthalmological diseases…).
This 220-pages report presents a comprehensive view of more than 580 products (type of product, development phase, indication, company). It includes synthetic figures showing global and detailed breakdown by development stage and by therapeutic area.
These highly-detailed informations provide a useful support to our « Landscape in… Gene Therapy Companies » that closely screens more than 230 companies involved in this expanding area.